

DERMALAC[®]ZYN



Probiotic Solution for Pediatric Atopic Dermatitis



Key marketing aspects

- > targeting the most frequent allergic disease in children
- > unique combination of patented probiotic strains specifically selected for the treatment of atopic dermatitis and for restoring the allergic immune system
- > plus vitamin D – health claim related to the normal function of the immune system and inflammatory response (EU No 432/2012)
- > 50% less allergy symptoms (pruritus, sleep loss, redness, swelling)
- > less emotional stress
- > alternative or add-on therapy to corticosteroids
- > clinically tested in children
- > high acceptance in children
- > pharmacy exclusive


How to use

- > lozenge: children above 3 years of age
- > sachet: children under 3 years of age
- > once a day
- > add-on to emollient & topical corticosteroids


Facts

- > randomized, placebo-controlled clinical trial (RCT) demonstrating significant reduction in clinical symptoms of atopic dermatitis in children¹
- > additional 3 RCTs published demonstrating improvements of other allergy symptoms^{2,3,4}
- > vitamin D modulates the immune response and helps alleviating symptoms of atopic dermatitis⁵
- > stimulating the Th1 immune response (INF- γ)⁶ and reducing key mediators (IL-4 & IgE) of allergic response¹

DermaLacZyn[®]




Placebo



DermaLacZyn® – The Leading Probiotic Solution for Atopic Dermatitis

Reducing symptoms of dermatitis from severe to mild!



Methods

- meta analysis of probiotics for the treatment of atopic dermatitis (AD) in children
- 198 studies published between 2000 and 2017 screened for the meta analysis
- finally 13 RCTs of children below 18 years included in the Meta Analysis
- AD severity was measured with the well-established Severity Scoring of Atopic Dermatitis (SCORAD index)
- SCORAD mean difference (MD) was used to measure the efficacy of probiotics in children with AD


Results

- significantly higher SCORAD values favoring *Lactobacilli* over placebo were observed
- the reported efficacy of probiotics in all RCTs was -3.07 (MD; CI: -7.45, -1.54)
- Lactobacillus rhamnosus* GG and *Lactobacillus plantarum* showed no significant effect on SCORAD values in children with AD
- DermaLacZyn® (MD -14.62; CI: -21.91, -7.33) containing *Lactobacillus paracasei* GMNL-133 was reported to be the most effective probiotic treatment for AD

Conclusion


- DermaLacZyn® is the most effective probiotic for the treatment of atopic dermatitis
- DermaLacZyn® effects are four times higher than the average over all probiotics
- the superior benefits of DermaLacZyn® can be contributed to differences in the species used

SCORAD reduction with probiotic treatment vs placebo



Source Huang et al. (2017)
Front Cell Infect Microbiol 7:392

Flow diagram of articles included in the meta analysis



References

- Wang & Wang, Clin Exp Allergy (2015), 2) Costa et al., Eur J Clin Nutr (2014), 3) Peng et al., Pediatr Allergy Immunol (2005), 4) Wang et al., Pediatr Allergy Immunol (2004), 5) Mutgji & Koo, Pediatr Dermatol (2013), 6) Lu et al., EP 2,581,461B1 (2011)



DermaLacZyn® is a registered trademark of BLUESTONE PHARMA GmbH | contact: info@bluestone-pharma.com

This publication does not constitute or provide scientific or medical advice, diagnosis, or treatment. This information is based on BSP's current knowledge and only contains scientific and technical information for business to business use. BSP makes no representation or warranty of the accuracy, reliability, or completeness of the information and as to results to be obtained. Use of this information shall be at your discretion and risk. It does not relieve you of your obligation to comply with all applicable laws and regulations and to observe all third party rights. Country or region-specific information should also be considered when labelling or advertising to final consumers. The content of this document is subject to change without further notice.